No Data
Baotou Dongbao Bio-tech: Summary of the 2024 Annual Report
Baotou Dongbao Bio-tech: 2025 First Quarter Report
Baotou Dongbao Bio-tech: 2024 Annual Report
Baotou Dongbao Bio-tech (300239.SZ): In the first quarter, the Net income was 19.04 million yuan, a year-on-year decrease of 26.64%.
Gelonghui, April 23丨Baotou Dongbao Bio-tech (300239.SZ) announced the first quarter report, with revenue of 0.188 billion yuan, a year-on-year decrease of 22.23%. The net income attributable to shareholders of the listed company was 19.04 million yuan, a year-on-year decrease of 26.64%. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 17.76 million yuan, a year-on-year decrease of 24.81%.
Baotou Dongbao Bio-tech (300239.SZ): The increase in tariffs has a relatively small impact on the company's overall performance.
On April 8, Glonghui reported that Baotou Dongbao Bio-tech (300239.SZ) stated on the investor interaction platform that the proportion of its exports to the USA in total revenue is relatively small, and the increase in tariffs has a minor impact on the company's overall performance.
Baotou Dongbao Bio-tech (300239.SZ): has cumulatively repurchased 1.24% of its shares.
On March 3, Gelonghui reported that Baotou Dongbao Bio-tech (300239.SZ) announced that as of February 28, 2025, the company has cumulatively repurchased 7,348,000 shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 1.2379% of the company's current total share capital, with a highest Fill Price of 5.71 yuan/share, a lowest Fill Price of 5.27 yuan/share, and a total transaction amount of 40.1431 million yuan (excluding transaction fees).
Not Many Are Piling Into Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Stock Yet As It Plummets 30%
